{
  "source": "PA-Notification-Tegsedi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1265-6\nProgram Prior Authorization/Notification\nMedication Tegsedi® (inotersen)\nP&T Approval Date 11/2018, 11/2020, 11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nTegsedi (inotersen) is a transthyretin-directed antisense oligonucleotide indicated for treatment\nof the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.\n2. Coverage Criteriaa:\nA. Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy\n1. Initial Authorization\na. Tegsedi will be approved based on all of the following criteria:\n(1) Diagnosis of hATTR amyloidosis with polyneuropathy\n-AND-\n(2) Patient has a pathogenic TTR mutation (e.g., V30M)\n-AND-\n(3) Patient is not receiving Tegsedi in combination with either of the following:\n(a) Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran)]\n(b) Tafamidis (e.g., Vyndaqel, Vyndamax)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tegsedi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Tegsedi therapy\n-AND-\n(2) Patient is not receiving Tegsedi in combination with either of the following:\n(a) Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran)]\n(b) Tafamidis (e.g., Vyndaqel, Vyndamax)\n© 2024 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may b",
    "on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Tegsedi [package insert]. Boston, MA: Akcea Therapeutics, Inc.; January 2024.\nProgram Prior Authorization/Notification – Tegsedi® (inotersen)\nChange Control\n11/2018 New program.\n11/2020 Annual review. Added examples of tafamidis products but no change to\nclinical intent. Updated reference.\n11/2021 Annual review with no changes to clinical criteria. Reference updated.\n11/2022 Annual review. Added Amvuttra (vutrisiran) as an example of not to be\nused in combination with no change in clinical intent. Added state\nmandate footnote. Updated reference.\n11/2023 Annual review with no change to coverage criteria.\n11/2024 Annual review with no change to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}